Clinical trial
Efficacy and Safety of Peginterferon Alfa-2a (40 KD) in Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment With Nucleoside (Nucleotide) Analogues - an Observational Study in Real-life Clinical Practice
NCT01794234 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Peginterferon Alfa-2a (40 KD) in Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment With Nucleoside (Nucleotide) Analogues - an Observational Study in Real-life Clinical Practice
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Observational
- Overall status
- Terminated
- Start date
- August 31, 2012
- Completion date
- September 30, 2013
- Enrollment
- 44 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.